GENOTYPE 1a

TABLE 113: SVR GENOTYPE 1A TREATMENT-EXPERIENCED WITH PARTIAL RESPONSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS-RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8	PR48	2.09 (0.81 to 6.19)	23.89 (−6.56 to 50.26)
SIM12 PR48		1.82 (0.58 to 5.78)	17.89 (−14.11 to 50.44)
PAR/RIT12 + OMB12 + DAS12 + RBV12		4.14 (1.97 to 11.79)	69.35 (37.44 to 86.62)
SIM12 PR48	T12 PR48 q8	0.88 (0.48 to 1.37)	−5.61 (−23.03 to 14.40)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.95 (1.34 to 3.71)	44.15 (20.84 to 66.13)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SIM12 PR48	2.24 (1.30 to 5.65)	49.92 (19.31 to 75.55)
Random effect model	Residual deviance	7.191 vs. 8 data points	
	Deviance information criteria	42.855	
Fixed effect model	Residual deviance	7.265 vs. 8 data points	
	Deviance information criteria	42.87	

CrI = credible interval; DAS = dasabuvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SVR = sustained virologic response; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.